PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-13.21%
Both companies show declining cash positions (-13.21% vs RVPH's -39.22%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-13.21%
Below half of RVPH's -39.22%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.76%
Other current assets growth < half of RVPH's 307.60%. David Dodd sees a leaner approach to short-term items.
-11.17%
Below half of RVPH's -31.82%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
7.73%
Higher PP&E (Net) Growth compared to RVPH's zero value, indicating better performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Both RVPH and the company show zero Long-Term Investments Growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
7.08%
Below half of RVPH's -100.00%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
-10.65%
Below half of RVPH's -31.82%. Michael Burry sees a potential red flag for stagnation or capital shortage.
-100.00%
Above 1.5x RVPH's -18.74%. Michael Burry questions if payables are being stretched to avoid short-term borrowing.
-100.00%
Higher Short-Term Debt Growth compared to RVPH's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Both RVPH and the company show zero Deferred Revenue (Current) Growth.
1577.51%
Exceeding 1.5x RVPH's 20.34%. Michael Burry suspects ballooning short-term obligations vs. competitor.
-26.01%
Less than half of RVPH's 8.62%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Higher Deferred Tax Liabilities (Non-Current) Growth compared to RVPH's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-0.35%
Less than half of RVPH's -1.96%. David Dodd sees a more conservative approach to non-current liabilities.
No Data
No Data available this quarter, please select a different quarter.
-6.06%
Less than half of RVPH's 7.71%. David Dodd sees far fewer liability expansions relative to competitor.
No Data
No Data available this quarter, please select a different quarter.
-3.82%
0.5-0.75x RVPH's -7.24%. Martin Whitman is wary of weaker retention or lower profitability.
100.00%
Higher AOCI Growth compared to RVPH's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-13.95%
Below half RVPH's -53.03%. Michael Burry sees potential underperformance in building shareholder capital.
-10.65%
Below half RVPH's -31.82%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
-100.00%
Both RVPH and the company show zero Total Investments Growth.
-4.69%
Higher Total Debt Growth compared to RVPH's zero value, indicating worse performance.
13.42%
Less than half of RVPH's 42.83%. David Dodd sees better deleveraging or stronger cash buildup than competitor.